These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20472168)

  • 1. Call for action to secure universal access to ART in developing countries.
    Orsi F; Carrieri MP; Coriat B; Delaporte E; Moatti JP; Spire B; Taverne B; Barré-Sinoussi F
    Lancet; 2010 May; 375(9727):1693-4. PubMed ID: 20472168
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic antiretroviral drugs--will they be the answer to HIV in the developing world?
    Kumarasamy N
    Lancet; 2004 Jul 3-9; 364(9428):3-4. PubMed ID: 15234833
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic HIV drugs--enlightened policy for global health.
    Wainberg MA
    N Engl J Med; 2005 Feb; 352(8):747-50. PubMed ID: 15728804
    [No Abstract]   [Full Text] [Related]  

  • 4. Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention.
    Gayle H; Lange JM
    Lancet; 2004 Jul 3-9; 364(9428):6-8. PubMed ID: 15234835
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinton brokers deal to lower price of antiretrovirals.
    Abimbola S
    BMJ; 2007 May; 334(7602):1026. PubMed ID: 17510129
    [No Abstract]   [Full Text] [Related]  

  • 6. Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world.
    Tucker T; Yeats J
    S Afr Med J; 2001 Aug; 91(8):615. PubMed ID: 11584766
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of generic antiretroviral therapy (ART) and free ART programs on time to initiation of ART at a tertiary HIV care center in Chennai, India.
    Solomon SS; Lucas GM; Kumarasamy N; Yepthomi T; Balakrishnan P; Ganesh AK; Anand S; Moore RD; Solomon S; Mehta SH
    AIDS Care; 2013 Aug; 25(8):931-6. PubMed ID: 23216257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating and Preventing HIV with Generic Drugs - Barriers in the United States.
    Martin EG; Schackman BR
    N Engl J Med; 2018 Jan; 378(4):316-319. PubMed ID: 29365306
    [No Abstract]   [Full Text] [Related]  

  • 9. Strategies to reduce risks in ARV supply chains in the developing world.
    Larson C; Burn R; Minnick-Sakal A; Douglas MO; Kuritsky J
    Glob Health Sci Pract; 2014 Dec; 2(4):395-402. PubMed ID: 25611474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic and branded drugs for the treatment of people living with HIV/AIDS.
    Bartlett JA; Muro EP
    J Int Assoc Physicians AIDS Care (Chic); 2007 Mar; 6(1):15-23. PubMed ID: 17329500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patents versus patients? Antiretroviral therapy in India.
    Havlir DV; Hammer SM
    N Engl J Med; 2005 Aug; 353(8):749-51. PubMed ID: 16120852
    [No Abstract]   [Full Text] [Related]  

  • 12. Scaling up antiretroviral treatment in resource-poor settings.
    Ellman T; Ford N
    Lancet; 2006 Aug; 368(9534):445-6. PubMed ID: 16890818
    [No Abstract]   [Full Text] [Related]  

  • 13. Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?
    Gutierrez JP; Johns B; Adam T; Bertozzi SM; Edejer TT; Greener R; Hankins C; Evans DB
    Lancet; 2004 Jul 3-9; 364(9428):63-4. PubMed ID: 15234857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic antiretroviral drugs and HIV care: An economic review.
    Yazdanpanah Y; Schwarzinger M
    Med Mal Infect; 2016 Mar; 46(2):67-71. PubMed ID: 26905394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic antiretroviral drugs in developing countries: friends or foes?
    Zucman D; Camara S; Gravisse J; Dimi S; Vasse M; Goudjo A; Choquet M; Peytavin G
    AIDS; 2014 Feb; 28(4):607-9. PubMed ID: 24378755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.
    Holmes CB; Coggin W; Jamieson D; Mihm H; Granich R; Savio P; Hope M; Ryan C; Moloney-Kitts M; Goosby EP; Dybul M
    JAMA; 2010 Jul; 304(3):313-20. PubMed ID: 20639565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can the generic antiretroviral industry support access to a universal antiretroviral regimen?
    Amole CD; Middlecote C; Prabhu VR; Kumarasamy N
    Curr Opin HIV AIDS; 2017 Jul; 12(4):390-397. PubMed ID: 28441147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
    HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy.
    O'Brien DP; Sauvageot D; Zachariah R; Humblet P;
    AIDS; 2006 Oct; 20(15):1955-60. PubMed ID: 16988517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.